Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study

Rheumatology International

Volumn 37, Issue 10, 2017, Pages 1709-1718

  Mena Vazquez, Natalia ^a   Manrique Arija, Sara ^a   Yunquera Romero, Lucía ^a   Ureña Garnica, Inmaculada ^a   Rojas Gimenez, Marta ^a   Domic, Carla ^a   Jimenez Nuñez, Francisco Gabriel ^a   Fernandez Nebro, Antonio ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Adherence; Biological disease modifying antirheumatic drugs (bDMARDs); Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ACTIVITY; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MORISKY GREEN TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85021090045     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-017-3758-6     Document Type: Article

References (50)

1. Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038
2. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1–26
3. Pasma A, van’t Spijker A, Hazes JM, Busschbach JJ, Luime JJ (2013) Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum 43(1):18–28
4. Wong PK (2016) Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe? Rheumatol Int 36(11):1535–1542
5. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44–47
6. Blum MA, Koo D, Doshi JA (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33(7):901–913
7. van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W (2009) Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 36(10):2164–2170
8. van den Bemt BJ, Zwikker HE, van den Ende CH (2012) Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol 8(4):337–351
9. Harrold LR, Andrade SE (2009) Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 38(5):396–402
10. Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K et al (2004) Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother 38(9):1357–1362
11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581
12. Val Jimenez A, Amoros Ballestero G, Martinez Visa P, Fernandez Ferre ML, Leon Sanroma M (1992) Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test. Aten Prim 10(5):767–770
13. Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24(1):67–74
14. Greenfield S, Apolone G, McNeil BJ, Cleary PD (1993) The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 31(2):141–154
15. Executive Summary of The Third Report of The (2001) National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19):2486–2497
16. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52(1):17–30
17. Hu G, Tuomilehto J, Borodulin K, Jousilahti P (2007) The joint associations of occupational, commuting, and leisure-time physical activity, and the Framingham risk score on the 10-year risk of coronary heart disease. Eur Heart J 28(4):492–498
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
19. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van Leeuwen LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48
20. Esteve-Vives J, Batlle-Gualda E, Reig A (1993) Spanish version of the health assessment questionnaire: reliability, validity and transcultural equivalency. Grupo para la Adaptacion del HAQ a la Poblacion Espanola. J Rheumatol 20(12):2116–2122
21. Park DC, Hertzog C, Leventhal H, Morrell RW, Leventhal E, Birchmore D et al (1999) Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc 47(2):172–183
22. Xia Y, Yin R, Fu T, Zhang L, Zhang Q, Guo G et al (2016) Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis. Patient Prefer Adher 10:735–742
23. van den Bemt BJ, van Lankveld WG (2007) How can we improve adherence to therapy by patients with rheumatoid arthritis? Nat Clin Pract Rheumatol 3:681 (United States)
24. Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L (2010) Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther 10(9):1367–1378
25. Salt E, Frazier SK (2010) Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs 29(4):260–275
26. Harley CR, Frytak JR, Tandon N (2003) Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 9(6 Suppl):S136–S143
27. Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA (2010) Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health 13(6):805–812
28. Chernew M, Gibson TB, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM (2008) Effects of increased patient cost sharing on socioeconomic disparities in health care. J Gen Intern Med 23(8):1131–1136
29. Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM et al (2011) Merging veterans affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken) 63(12):1680–1690
30. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr., Griffin MR (2007) Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 45(10 Supl 2):S66–S76
31. de Thurah A, Norgaard M, Harder I, Stengaard-Pedersen K (2010) Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine. A prospective cohort study. Rheumatol Int 30(11):1441–1448
32. Deyo RA, Inui TS, Sullivan B (1981) Noncompliance with arthritis drugs: magnitude, correlates, and clinical implications. J Rheumatol 8(6):931–936
33. Sauer BC, Teng CC, Tang D, Leng J, Curtis JR, Mikuls TR et al (2017) Persistence with conventional triple therapy versus a tumor necrosis factor inhibitor and methotrexate in US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 69(3):313–322
34. Agarwal S, Zaman T, Handa R (2009) Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Singapore Med J 50(7):686–692
35. Hoekstra M et al (2006) Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol 33(3):481–485
36. Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SMM (2016) Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open 2(1):e000171
37. Sandoval LF, Huang KE, Feldman SR (2013) Adherence to ustekinumab in psoriasis patients. J Drugs Dermatol 12(10):1090–1092
38. Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR (2004) Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 63(11):1372–1378
39. Jarry JL, Coambs RB, De Maio FG, Rattray AH, Balaram R, Russell A (2002) Projected patterns of compliance associated with Remicade (infliximab) and Enbrel (etanercept) [abstract]. J Rheumatol 29:1564
40. Rueda Gotor J, Blanco Alonso R (2011) Tocilizumab in rheumatoid arthritis. Reumatol Clin 6s3:S29–S32
41. de Thurah A, Norgaard M, Johansen MB, Stengaard-Pedersen K (2010) Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study. Scand J Rheumatol 39(3):197–205
42. Aletaha D, Smolen JS (2002) Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 29(8):1631–1638
43. Knobel H, Alonso J, Casado JL, Collazos J, Gonzalez J, Ruiz I et al (2002) Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. Aids 16(4):605–613
44. Thompson K, Kulkarni J, Sergejew AA (2000) Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 42(3):241–247
45. Chang MC, Chang YC, Chiou JF, Tsou TS, Lin CC (2002) Overcoming patient-related barriers to cancer pain management for home care patients. A pilot study. Cancer Nurs 25(6):470–476
46. Turbi C, Herrero-Beaumont G, Acebes JC, Torrijos A, Grana J, Miguelez R et al (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26(2):245–256
47. Davis NJ, Billett HH, Cohen HW, Arnsten JH (2005) Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother 39(4):632–636
48. Pineiro F, Gil V, Donis M, Orozco D, Torres MT, Merino J (1997) The validity of 6 indirect methods for assessing compliance with pharmacological treatment in dyslipidemias. Aten Prim 19(9):465–468
49. Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G G, Lazovskis J et al (2009) Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 68(11):1666–1672
50. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T et al (2014) Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 73(1):198–206